| James Metcalfe Culver, MD | |
|
600 Peter Jefferson Pkwy, Ste 290, Charlottesville, VA 22911 | |
| (434) 977-4488 | |
| (434) 977-6103 |
| Full Name | James Metcalfe Culver |
|---|---|
| Gender | Male |
| Speciality | Obstetrics/gynecology |
| Experience | 26 Years |
| Location | 600 Peter Jefferson Pkwy, Charlottesville, Virginia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1922064278 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | 0101234810 (Virginia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Sentara Martha Jefferson Hospital | Charlottesville, VA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Jefferson Ob Gyn Ltd | 1355381724 | 12 |
News Archive
A new study has looked into the artificial increase in the level of 'good' cholesterol and its link to the reversal of atherosclerosis in arteries.
Asia, Europe, Africa... The bird flu epidemic has not needed a passport to cross borders, but has almost certainly required a vector.
AstraZeneca and Targacept, Inc. today announced initiation of a Phase 2b clinical trial of TC-5214, a nicotinic channel blocker, as a "switch" monotherapy treatment for patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant therapy. This study is in addition to the companies' Phase 3 RENAISSANCE Program for TC-5214 as an adjunctive treatment for MDD.
Mylan Inc. today announced that its U.S.-based subsidiary Mylan Pharmaceuticals Inc. has launched Tolterodine Tartrate Extended-release Capsules, 2 mg and 4 mg. Tolterodine Tartrate ER Capsules are the generic version of Pfizer's Detrol LA, and are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency. Mylan received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for this product.
A team of Canadian and Japanese researchers has identified the genetic mutation responsible for glycogen storage disease type IIIa in Inuit in northern Quebec, Canada, in a study published in CMAJ (Canadian Medical Association Journal).
› Verified 4 days ago
| Entity Name | Virginia Physicians For Women, Ltd |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1639137979 PECOS PAC ID: 8628057924 Enrollment ID: O20040720000074 |
News Archive
A new study has looked into the artificial increase in the level of 'good' cholesterol and its link to the reversal of atherosclerosis in arteries.
Asia, Europe, Africa... The bird flu epidemic has not needed a passport to cross borders, but has almost certainly required a vector.
AstraZeneca and Targacept, Inc. today announced initiation of a Phase 2b clinical trial of TC-5214, a nicotinic channel blocker, as a "switch" monotherapy treatment for patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant therapy. This study is in addition to the companies' Phase 3 RENAISSANCE Program for TC-5214 as an adjunctive treatment for MDD.
Mylan Inc. today announced that its U.S.-based subsidiary Mylan Pharmaceuticals Inc. has launched Tolterodine Tartrate Extended-release Capsules, 2 mg and 4 mg. Tolterodine Tartrate ER Capsules are the generic version of Pfizer's Detrol LA, and are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency. Mylan received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for this product.
A team of Canadian and Japanese researchers has identified the genetic mutation responsible for glycogen storage disease type IIIa in Inuit in northern Quebec, Canada, in a study published in CMAJ (Canadian Medical Association Journal).
› Verified 4 days ago
| Entity Name | Dominion Women's Health, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1932289592 PECOS PAC ID: 1456327824 Enrollment ID: O20040907001241 |
News Archive
A new study has looked into the artificial increase in the level of 'good' cholesterol and its link to the reversal of atherosclerosis in arteries.
Asia, Europe, Africa... The bird flu epidemic has not needed a passport to cross borders, but has almost certainly required a vector.
AstraZeneca and Targacept, Inc. today announced initiation of a Phase 2b clinical trial of TC-5214, a nicotinic channel blocker, as a "switch" monotherapy treatment for patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant therapy. This study is in addition to the companies' Phase 3 RENAISSANCE Program for TC-5214 as an adjunctive treatment for MDD.
Mylan Inc. today announced that its U.S.-based subsidiary Mylan Pharmaceuticals Inc. has launched Tolterodine Tartrate Extended-release Capsules, 2 mg and 4 mg. Tolterodine Tartrate ER Capsules are the generic version of Pfizer's Detrol LA, and are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency. Mylan received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for this product.
A team of Canadian and Japanese researchers has identified the genetic mutation responsible for glycogen storage disease type IIIa in Inuit in northern Quebec, Canada, in a study published in CMAJ (Canadian Medical Association Journal).
› Verified 4 days ago
| Entity Name | Jefferson Ob Gyn Ltd |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1538197454 PECOS PAC ID: 1355381724 Enrollment ID: O20050504001072 |
News Archive
A new study has looked into the artificial increase in the level of 'good' cholesterol and its link to the reversal of atherosclerosis in arteries.
Asia, Europe, Africa... The bird flu epidemic has not needed a passport to cross borders, but has almost certainly required a vector.
AstraZeneca and Targacept, Inc. today announced initiation of a Phase 2b clinical trial of TC-5214, a nicotinic channel blocker, as a "switch" monotherapy treatment for patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant therapy. This study is in addition to the companies' Phase 3 RENAISSANCE Program for TC-5214 as an adjunctive treatment for MDD.
Mylan Inc. today announced that its U.S.-based subsidiary Mylan Pharmaceuticals Inc. has launched Tolterodine Tartrate Extended-release Capsules, 2 mg and 4 mg. Tolterodine Tartrate ER Capsules are the generic version of Pfizer's Detrol LA, and are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency. Mylan received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for this product.
A team of Canadian and Japanese researchers has identified the genetic mutation responsible for glycogen storage disease type IIIa in Inuit in northern Quebec, Canada, in a study published in CMAJ (Canadian Medical Association Journal).
› Verified 4 days ago
| Entity Name | Obhg Virginia Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1972807394 PECOS PAC ID: 9436323342 Enrollment ID: O20111110000430 |
News Archive
A new study has looked into the artificial increase in the level of 'good' cholesterol and its link to the reversal of atherosclerosis in arteries.
Asia, Europe, Africa... The bird flu epidemic has not needed a passport to cross borders, but has almost certainly required a vector.
AstraZeneca and Targacept, Inc. today announced initiation of a Phase 2b clinical trial of TC-5214, a nicotinic channel blocker, as a "switch" monotherapy treatment for patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant therapy. This study is in addition to the companies' Phase 3 RENAISSANCE Program for TC-5214 as an adjunctive treatment for MDD.
Mylan Inc. today announced that its U.S.-based subsidiary Mylan Pharmaceuticals Inc. has launched Tolterodine Tartrate Extended-release Capsules, 2 mg and 4 mg. Tolterodine Tartrate ER Capsules are the generic version of Pfizer's Detrol LA, and are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency. Mylan received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for this product.
A team of Canadian and Japanese researchers has identified the genetic mutation responsible for glycogen storage disease type IIIa in Inuit in northern Quebec, Canada, in a study published in CMAJ (Canadian Medical Association Journal).
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| James Metcalfe Culver, MD 600 Peter Jefferson Pkwy, Ste 290, Charlottesville, VA 22911 Ph: (434) 977-4488 | James Metcalfe Culver, MD 600 Peter Jefferson Pkwy, Ste 290, Charlottesville, VA 22911 Ph: (434) 977-4488 |
News Archive
A new study has looked into the artificial increase in the level of 'good' cholesterol and its link to the reversal of atherosclerosis in arteries.
Asia, Europe, Africa... The bird flu epidemic has not needed a passport to cross borders, but has almost certainly required a vector.
AstraZeneca and Targacept, Inc. today announced initiation of a Phase 2b clinical trial of TC-5214, a nicotinic channel blocker, as a "switch" monotherapy treatment for patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant therapy. This study is in addition to the companies' Phase 3 RENAISSANCE Program for TC-5214 as an adjunctive treatment for MDD.
Mylan Inc. today announced that its U.S.-based subsidiary Mylan Pharmaceuticals Inc. has launched Tolterodine Tartrate Extended-release Capsules, 2 mg and 4 mg. Tolterodine Tartrate ER Capsules are the generic version of Pfizer's Detrol LA, and are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency. Mylan received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for this product.
A team of Canadian and Japanese researchers has identified the genetic mutation responsible for glycogen storage disease type IIIa in Inuit in northern Quebec, Canada, in a study published in CMAJ (Canadian Medical Association Journal).
› Verified 4 days ago
Donald J. Dudley, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1204 W Main St, Charlottesville, VA 22908 Phone: 434-924-2500 Fax: 434-244-9487 | |
Christian A. Chisholm, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1204 W Main St, Charlottesville, VA 22903 Phone: 434-924-2500 Fax: 434-244-9487 | |
Jennifer Doorey, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 2955 Ivy Rd Ste 304, Charlottesville, VA 22903 Phone: 434-243-4570 Fax: 434-295-5491 | |
Evan Jacob Kraus, Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 600 Peter Jefferson Pkwy, Charlottesville, VA 22911 Phone: 434-977-4488 | |
Charles N. Landen Jr., M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1240 Lee St, Charlottesville, VA 22908 Phone: 434-924-5100 Fax: 434-982-1840 | |
Dr. Linnea Rose Goodman, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 4100 Olympia Cir Ste 201, Charlottesville, VA 22911 Phone: 434-220-6620 Fax: 434-220-6621 | |
Ms. Whitney Dijon Archie-patrick, FNP Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 2955 Ivy Rd Ste 304, Charlottesville, VA 22903 Phone: 434-243-4570 Fax: 434-295-5491 |